TY - JOUR
T1 - The background, discovery and clinical development of BCR-ABL inhibitors
AU - Lambert, G.K.
AU - Duhme-Klair, A.-K.
AU - Morgan, T.
AU - Ramjee, M.K.
N1 - ©2013 Elsevier Ltd. All rights reserved.
PY - 2013/10
Y1 - 2013/10
N2 - The story of the inhibition of BCR-ABL as a treatment for chronic myelogenous leukaemia serves to illustrate key aspects of the kinase drug discovery and development process. Firstly, elucidation of the disease mechanism enabled identification of the molecular target(s) which catalysed pharmaceutical research and resulted in Gleevec
AB - The story of the inhibition of BCR-ABL as a treatment for chronic myelogenous leukaemia serves to illustrate key aspects of the kinase drug discovery and development process. Firstly, elucidation of the disease mechanism enabled identification of the molecular target(s) which catalysed pharmaceutical research and resulted in Gleevec
UR - http://www.scopus.com/inward/record.url?scp=84884595281&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2013.06.001
DO - 10.1016/j.drudis.2013.06.001
M3 - Article
AN - SCOPUS:84884595281
SN - 1359-6446
VL - 18
SP - 992
EP - 999
JO - Drug discovery today
JF - Drug discovery today
IS - 19-20
ER -